Thank you for the thread link. There is still some catching up...

Thank you for the thread link. There is still some catching up to do on my behalf. Always grateful for links and references!

I fully agree with your comment about the apparent synergyhereand the obvious advantages it could bring (all depending on clinical results of course):

• each CAR receptor (CLTX and CDH17) a valuable autologous therapy in its own right and while they advance through the clinics...
• ... future next-generation products (multiple) are to also benefit from CLTX and CDH17 CAR clinical trial data...
• ... combined with our allogeneic CORE-NK platform - also a valuable therapy in its own right - ...
• ... being the starting point of a whole new "supercharged" CORE-NK platform that will give rise to a whole new pipeline of therapies...
• ... that unlike our autologous CAR receptors, could be a true "off-the-shelf" solution, readily available to patients with generally don't have the luxury of waiting for their personalised (autologous) treatment to be ready ("ultimately it will make available a high quality and highly potent treatment to patients on the spot without delay, which means it takes away the opportunity for the cancer to grow for another month and possibly making it impossible to treat")

What also piqued my interest, is the "Undisclosed CAR NK" to be used in CHM 3301. Obviously with Nature covering the CORE-NK platform back in 2019 (article received in April, published in October) and CDH17 this month (article received in May 2021, published in March 2022), we may have already read about it or will be reading about it in Nature, too. Based on published material, we may be getting another licensing agreement soon, turning the undisclosed CAR NK into a disclosed one.